DOWNLOAD PDF

Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations

*Emmanuel Ifeanyi Obeagu1, Getrude Uzoma Obeagu2, Joseph Obiezu Chukwujekwu Ezeonwumelu3, Frances Ugonne Ogunnaya4, Anthonia Onyinye Ngwoke5, Obioma Raluchukwu Emeka-Obi6 and Okechukwu Paul-Chima Ugwu7

1Department of Medical Laboratory Science, Kampala International University, Uganda.

2School of Nursing Science, Kampala International University, Uganda.

3Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy, Kampala International University, Western Campus, Ishaka, Bushenyi, Uganda.

4Department of Internal Medicine, Newark Beth Israel Medical Center, 201 Lyons Avenue, Newark NJ.

5Department of Human Physiology, Faculty of Basic Medical Sciences, Enugu State University of Science and Technology, Enugu State, Nigeria.

6Department of Biochemistry, Faculty of Science, Kingsley Ozumba Mbadiwe University, Ideato, Imo State, Nigeria.

7Department of Publication and Extensions, Kampala International University, Uganda.

*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda.

E-mail: emmanuelobeagu@yahoo.com, obeagu.emmanuel@kiu.ac.ug, ORCID: 0000-0002-4538-0161

ABSTRACT

HIV infection presents multifaceted challenges, particularly in managing hematologic complications that significantly impact patient well-being and prognosis. Hematologic manifestations such as anemia, thrombocytopenia, and coagulopathies are prevalent in individuals living with HIV, necessitating meticulous attention and specialized care. Among the array of interventions, blood transfusions play a pivotal role in addressing these hematologic complications. However, the complexities surrounding blood transfusion strategies in the context of HIV extend beyond mere hematologic support and delve into intricate immunological considerations. This paper aims to elucidate the nuanced landscape of hematologic support in HIV patients, focusing specifically on blood transfusion strategies and their immunological implications. The review encompasses an in-depth analysis of hematologic abnormalities commonly encountered in HIV, exploring the prevalence, etiology, and clinical impact of anemia, thrombocytopenia, and coagulopathies. Additionally, it examines the indications, safety measures, and challenges associated with blood transfusion therapy in this population. Furthermore, the paper delineates the intricate interplay between blood transfusions and the immunological milieu of HIV-infected individuals. It explores the immunomodulatory effects of transfusions, potential immune activation, and the impact on disease progression, while also addressing concerns regarding alloimmunization and the modulation of immune responses post-transfusion. By synthesizing current evidence and insights, this paper delineates the clinical outcomes, challenges, and controversies surrounding blood transfusion strategies in HIV care. It underscores the need for optimized transfusion practices tailored to the unique immunological landscape of HIV patients and highlights avenues for future research and advancements in clinical practice. In conclusion, this paper serves as a comprehensive resource elucidating hematologic support through blood transfusion strategies in HIV patients, providing a foundation for informed decision-making and paving the way for enhanced care paradigms in the management of hematologic complications in HIV.

Keywords: Hematologic Support, HIV, Patients and Blood Transfusion

 INTRODUCTION

Human Immunodeficiency Virus (HIV) infection remains a global health challenge, characterized not only by its impact on the immune system but also by its intricate interactions with hematologic components, presenting a spectrum of challenges in clinical management [1]. Among the myriad complications associated with HIV, hematologic abnormalities such as anemia, thrombocytopenia, and coagulopathies are prevalent, contributing significantly to morbidity and mortality in affected individuals [2]. The delicate balance of maintaining adequate hematologic parameters while navigating the complexities of HIV-related immunosuppression necessitates a nuanced approach to patient care [3]. Hematologic support, particularly through blood transfusions, emerges as a critical component in addressing the hematologic sequelae of HIV infection [4]. However, the utilization of blood transfusion strategies in this context requires meticulous consideration of immunological factors, beyond the conventional focus on hematologic correction. This paper endeavors to delineate the intricate interplay between hematologic support, blood transfusion strategies, and their immunological implications in the management of HIV-infected individuals. It aims to elucidate the prevalence, etiology, and clinical impact of hematologic manifestations associated with HIV, emphasizing the significance of tailored interventions to mitigate these complications. Furthermore, the paper seeks to explore the multifaceted landscape of blood transfusion strategies in HIV care. It delves into the indications, challenges, and safety considerations associated with transfusion therapy in this specific patient population. Beyond addressing hematologic deficits, it aims to unravel the complex immunological ramifications of blood transfusions in individuals living with HIV. The intersection between blood transfusions and the immune system in HIV-infected individuals remains a domain replete with uncertainties and evolving paradigms [5]. Therefore, this review endeavors to consolidate existing knowledge, critically analyze current evidence, and provide insights into optimizing blood transfusion practices, while considering the intricate immunological milieu of HIV. In essence, by synthesizing multifaceted aspects of hematologic support and blood transfusion strategies in the context of HIV, this review aims to contribute to a deeper understanding of tailored interventions, paving the way for improved clinical management and better outcomes for individuals navigating the intricate intersection of HIV infection and hematologic challenges.

Hematologic Manifestations of HIV

HIV infection has profound effects on the hematologic system, leading to various manifestations and complications that significantly impact the health and prognosis of affected individuals. Anemia is one of the most prevalent hematologic abnormalities in HIV-infected individuals. It can be caused by multiple factors, including the direct effects of the virus on bone marrow function, chronic inflammation, opportunistic infections, nutritional deficiencies, or side effects of medications used in HIV treatment. Anemia can contribute to fatigue, decreased quality of life, and increased disease progression [6-15]. HIV infection often leads to a decrease in platelet count, resulting in thrombocytopenia [16]. This condition might arise due to bone marrow suppression, immune-mediated destruction of platelets, or infections such as HIV-associated immune thrombocytopenic purpura (ITP). Thrombocytopenia increases the risk of bleeding and bruising in affected individuals. HIV infection can disrupt the body’s coagulation cascade, leading to various coagulation abnormalities such as increased clotting (thrombophilia) or bleeding tendencies (hemorrhagic disorders) [18]. These alterations in coagulation factors may predispose individuals to venous thromboembolic events or bleeding complications. HIV can directly affect bone marrow function, leading to suppression of hematopoiesis [18]. This suppression results in decreased production of red blood cells, white blood cells, and platelets, contributing to the development of anemia, leukopenia, and thrombocytopenia, respectively. HIV infection increases the risk of certain hematologic malignancies, including non-Hodgkin lymphoma and leukemia. These conditions can arise due to the direct impact of the virus on the immune system, persistent immune activation, or co-infections such as Epstein-Barr virus or human herpesvirus 8. Managing hematologic manifestations in HIV requires a comprehensive approach that involves monitoring blood counts, identifying underlying causes, and initiating appropriate treatments. This may include the use of antiretroviral therapy to control viral replication, addressing nutritional deficiencies, administering erythropoietin-stimulating agents for anemia, and employing therapies tailored to specific hematologic complications [19-28]. Understanding and addressing these hematologic manifestations are crucial in improving the overall care and quality of life for individuals living with HIV, as these manifestations can significantly impact the progression of the disease and the individual’s health outcomes. Regular monitoring and timely intervention are essential to manage these hematologic complications effectively.

Blood Transfusion Strategies in HIV Patients

Blood transfusion strategies in HIV patients require a careful and tailored approach due to the specific challenges posed by the virus and its impact on the immune system [29]. The decision to transfuse blood products in HIV patients should follow established guidelines and be based on clinical indications such as severe anemia, acute bleeding, thrombocytopenia-associated bleeding, or coagulation disorders. Additionally, patient-specific factors including symptoms, hemoglobin levels, platelet counts, and coexisting medical conditions need to be considered. Selection of blood products, including packed red blood cells (PRBCs), platelets, and clotting factors, should be based on the specific needs of the individual patient. For instance, in cases of anemia, PRBC transfusions may be necessary to address low hemoglobin levels, while platelet transfusions might be required for severe thrombocytopenia-related bleeding [30-34]. Ensuring the safety of blood transfusions in HIV patients involves stringent screening processes for donated blood to minimize the risk of transfusion-transmissible infections, including HIV [35]. Use of appropriately screened and tested blood products is crucial to prevent transmission of additional infections or complications. The immunological effects of blood transfusions in HIV patients are of particular importance [36]. Transfusions may lead to alterations in the recipient’s immune response, potentially affecting the HIV disease course or immune activation. Understanding these immunological consequences is essential in managing HIV patients who require transfusions. HIV patients receiving blood transfusions are susceptible to specific complications such as transfusion reactions, alloimmunization, and potential effects on viral load and immune activation [37]. Monitoring for adverse reactions and complications post-transfusion is crucial for optimal patient care. In certain situations, alternatives to transfusions, such as erythropoietin-stimulating agents for anemia or specific medications to address thrombocytopenia, may be considered to minimize the need for blood products or to complement transfusion strategies in HIV patients [38]. Tailoring transfusion practices based on individual patient needs, optimizing dosing, and evaluating the benefits against potential risks are essential components in the overall management of HIV patients requiring blood transfusions [39]. Understanding the nuances of blood transfusion strategies in HIV patients involves a multidisciplinary approach that integrates hematologic considerations, immunological effects, and patient-specific factors. Close monitoring and adherence to established guidelines help in ensuring the safety and efficacy of transfusion therapy in this patient population.

 Immunological Considerations

In the context of blood transfusions in HIV patients, immunological considerations play a crucial role. HIV infection is characterized by chronic immune activation and inflammation [40]. Blood transfusions have the potential to further stimulate the immune system, potentially exacerbating these conditions. The interaction between transfused blood components and the recipient’s immune system might contribute to heightened immune activation, impacting the progression of HIV and complicating the management of the disease. There’s ongoing debate regarding the impact of blood transfusions on HIV viral load in recipients. Transfusions may transiently affect viral load due to factors such as the introduction of donor immune cells or cytokines, but the long-term effects remain uncertain [41]. Close monitoring of viral load post-transfusion is essential to assess any changes and their implications for disease management. HIV patients receiving multiple transfusions are at risk of developing alloimmunization—production of antibodies against transfused blood antigens [42]. Alloimmunization can complicate future transfusions by causing adverse reactions, reducing the effectiveness of transfused products, and limiting the availability of compatible blood. Managing alloimmunization in HIV patients requires careful consideration and appropriate blood product selection. Blood transfusions may exert immune-modulating effects on the recipient’s immune system [43]. These effects could impact the balance between immune tolerance and activation, potentially influencing the progression of HIV and the overall immune response. HIV patients often have compromised immune systems, making them more susceptible to opportunistic infections [44]. Alterations in the immune response due to blood transfusions might influence susceptibility to certain infections or affect the course of existing opportunistic diseases. Considering the immunological effects of transfusions, exploring strategies to modulate the recipient’s immune response post-transfusion in HIV patients is an area of interest. Research into interventions that could mitigate potential immune activation or modulate immune tolerance after transfusions might offer new avenues for optimizing care. Regular monitoring of immune parameters, including markers of immune activation and function, can provide insights into the immunological consequences of blood transfusions in HIV patients [45]. This monitoring aids in assessing the impact on the immune system and guiding appropriate interventions or adjustments in patient management. Understanding the intricate immunological considerations associated with blood transfusions in HIV patients is critical for optimizing patient care. Balancing the benefits of transfusions against potential immunological consequences requires careful assessment, monitoring, and a nuanced approach tailored to the individual patient’s needs and clinical status.

Clinical Outcomes

In the realm of blood transfusions in HIV patients, several clinical outcomes and challenges arise, influencing patient care and management. Blood transfusions aim to improve hematologic parameters such as hemoglobin levels, platelet counts, and clotting factors, thereby alleviating symptoms related to anemia, thrombocytopenia, or coagulation disorders in HIV patients [46]. Transfusions can alleviate symptoms associated with hematologic complications, such as fatigue due to anemia or bleeding episodes related to thrombocytopenia, enhancing the patient’s quality of life [47]. Blood transfusions are crucial in emergency situations such as severe anemia, acute bleeding, or surgical interventions, where immediate restoration of blood components is essential for the patient’s stability and recovery [48]. Appropriate transfusion strategies may prevent severe complications and reduce the risk of morbidity and mortality associated with untreated hematologic abnormalities in HIV-infected individuals.

Challenges

Despite stringent screening protocols, there’s always a risk of transfusion-transmitted infections. HIV patients are particularly vulnerable, and ensuring the safety of blood products remains a significant challenge [49]. The complex interplay between blood transfusions and the immune system in HIV patients poses challenges in understanding and managing potential immune activation, alloimmunization, and their consequences on disease progression. Determining the optimal timing and frequency of blood transfusions in HIV patients remains a challenge [50]. Balancing the need for transfusions against potential risks and complications requires careful assessment and individualized approaches. HIV patients receiving multiple transfusions are at risk of developing alloantibodies, limiting the availability of compatible blood products and increasing the risk of adverse reactions during subsequent transfusions [51]. Resource limitations, including access to safe blood products, appropriate testing facilities, and specialized transfusion services, may hinder the provision of optimal transfusion support to HIV-infected individuals, particularly in resource-limited settings [52]. Understanding the long-term effects of repeated transfusions on HIV disease progression, immune function, and overall clinical outcomes remains an ongoing challenge that requires further research and investigation. Addressing these challenges while maximizing the clinical benefits of blood transfusions in HIV patients involves a multidisciplinary approach, stringent monitoring, adherence to safety protocols, and ongoing research to optimize transfusion practices in this unique patient population.

CONCLUSION

In conclusion, the management of hematologic complications through blood transfusions in individuals living with HIV presents a multifaceted landscape that intertwines hematologic, immunological, and clinical considerations. The intricate balance between addressing hematologic deficits and navigating potential immunological consequences poses challenges and opportunities in optimizing patient care. Blood transfusions play a pivotal role in alleviating symptoms associated with anemia, thrombocytopenia, or coagulation disorders in HIV-infected individuals, thereby improving their quality of life and preventing severe complications. However, navigating the immunological implications of transfusions in the context of HIV requires careful assessment and consideration. Immunological considerations, such as immune activation, alloimmunization, and the impact on viral load and disease progression, underscore the need for a nuanced approach to transfusion strategies. Understanding the complex interplay between transfused blood components and the recipient’s immune system is crucial in tailoring interventions and mitigating potential adverse effects. The challenges of ensuring transfusion safety, managing immune responses, determining optimal timing and frequency, and addressing resource limitations necessitate a multidisciplinary approach involving hematologists, infectious disease specialists, transfusion medicine experts, and immunologists.

REFERENCES

  1. Vishnu, P., & Aboulafia, D. M. (2015). Haematological manifestations of human immune deficiency virus infection. British journal of haematology, 171(5), 695-709.
  2. Volberding, P. A., Baker, K. R., & Levine, A. M. (2003). Human immunodeficiency virus hematology. ASH Education Program Book, 2003(1), 294-313.
  3. Crespo-Fierro, M. (2018). Culture Care Needs of Puerto Rican Women Receiving HIV Care from Nurse Practitioners in New York City.
  4. Thachil, J., Owusu-Ofori, S., & Bates, I. (2014). Haematological diseases in the tropics. Manson’s Tropical Infectious Diseases, 894.
  5. Livingston, J. (2012). Improvising medicine: an African oncology ward in an emerging cancer epidemic. Duke University Press.
  6. Obeagu, E. I., Alum, E. U., & Obeagu, G. U. (2023). Factors associated with prevalence of HIV among youths: A review of Africa perspective. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035, 3(1), 13-18.
  7. Obeagu, E. I. (2023). A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035, 3(1), 7-12.
  8. Obeagu, E. I., & Onuoha, E. C. (2023). A review of factors influencing the utilization of HIV/AIDS prevention methods among secondary school students. J. Adv. Multidiscip. Res, 10(10), 49-55.
  9. Obeagu, E. F., Onyenweaku, F. C., Nwobodo, H. A., Ochei, K. C., Ochiabuto Ogochukwu, M. T. B., & Onwuasoanya, U. F. (2017). Impact of HIV and hepatitis b virus coinfection on selected haematological markers of the patients in Umuahia, Abia State, Nigeria. Ann Clin Lab Res, 5(2), 175.
  10. Obeagu, E. I., & Onuoha, E. C. (2023). Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. J. Adv. Res. Biol. Sci, 10(9), 128-134.
  11. Obeagu, E. I., Obeagu, G. U., Musiimenta, E., Bot, Y. S., & Hassan, A. O. (2023). Factors contributing to low utilization of HIV counseling and testing services. J. Curr. Res. Med. Sci, 9(2), 1-5.
  12. Obeagu, E. I., Okwuanaso, C. B., Edoho, S. H., & Obeagu, G. U. (2022). Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035, 2(3), 120-127.
  13. Obeagu, E. I., & Obeagu, G. U. (2023). A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. J. Adv. Res. Biol. Sci, 10(9), 135-142.
  14. Obeagu, E. I., Ochei, K. C., Okeke, E. I., & Anode, A. C. (2016). Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. J. Curr. Res. Med. Sci, 2(4), 29-33.
  15. Obeagu, E. I., Scott, G. Y., Amekpor, F., Ofodile, A. C., Edoho, S. H., & Ahamefula, C. (2022). Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035, 2(3), 128-134.
  16. Vishnu, P., & Aboulafia, D. M. (2015). Haematological manifestations of human immune deficiency virus infection. British journal of haematology, 171(5), 695-709.
  17. Goeijenbier, M., Van Wissen, M., Van De Weg, C., Jong, E., Gerdes, V. E. A., Meijers, J. C. M., … & Van Gorp, E. C. M. (2012). Viral infections and mechanisms of thrombosis and bleeding. Journal of medical virology, 84(10), 1680-1696.
  18. Pascutti, M. F., Erkelens, M. N., & Nolte, M. A. (2016). Impact of viral infections on hematopoiesis: from beneficial to detrimental effects on bone marrow output. Frontiers in immunology, 7, 364.
  19. Offie, D. C., Obeagu, E. I., Akueshi, C., Njab, J. E., Ekanem, E. E., Dike, P. N., & Oguh, D. N. (2021). Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. Journal of Pharmaceutical Research International, 33(52B), 10-19.
  20. Obeagu, E. I., Ogbonna, U. S., Nwachukwu, A. C., Ochiabuto, O., Enweani, I. B., & Ezeoru, V. C. (2021). Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International, 33(4), 10-19.
  21. Obeagu, E. I., Ibeh, N. C., Nwobodo, H. A., Ochei, K. C., & Iwegbulam, C. P. (2017). Haematological indices of malaria patients coinfected with HIV in Umuahia. J. Curr. Res. Med. Sci, 3(5), 100-104.
  22. Obeagu, E. I., & Obeagu, G. U. (2023). Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. J. Adv. Multidiscip. Res, 10(10), 56-62.
  23. Walter, O., Anaebo, Q. B. N., Obeagu, E. I., & Okoroiwu, I. L. (2022). Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International, 29-34.
  24. Ezeoru, V. C., Enweani, I. B., Ochiabuto, O., Nwachukwu, A. C., Ogbonna, U. S., & Obeagu, E. I. (2021). Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. Journal of Pharmaceutical Research International, 33(4), 10-19.
  25. Alum, E. U., Obeagu, E. I., Ugwu, O. P., Samson, A. O., Adepoju, A. O., & Amusa, M. O. (2023). Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine, 102(41), e35673.
  26. Vincent, C. C. N., Obeagu, E. I., Agu, I. S., Ukeagu, N. C., & Onyekachi-Chigbu, A. C. (2021). Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International, 33(57A), 360-368.
  27. Obeagu, E. I., Eze, V. U., Alaeboh, E. A., & Ochei, K. C. (2016). Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. J BioInnovation, 5, 464-71.
  28. Obeagu, E. I., Scott, G. Y., Amekpor, F., & Obeagu, G. U. (2023). Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. J. Curr. Res. Med. Sci, 9(2), 6-13.
  29. Barro, L., Drew, V. J., Poda, G. G., Tagny, C. T., El‐Ekiaby, M., Owusu‐Ofori, S., & Burnouf, T. (2018). Blood transfusion in sub‐Saharan Africa: understanding the missing gap and responding to present and future challenges. Vox Sanguinis, 113(8), 726-736.
  30. Basu, D., & Kulkarni, R. (2014). Overview of blood components and their preparation. Indian journal of anaesthesia, 58(5), 529.
  31. Obeagu EI, Babar Q, Obeagu GU. Allergic blood Transfusion reaction: A Review. Int. J. Curr. Res. Med. Sci. 2021;7(5):25-33.
  32. Obeagu EI, Oshim IO, Ochei KC, Obeagu GU. Iron and blood donation: A Review. Int. J. Curr. Res. Med. Sci. 2016;2(10):16-48.
  33. Okoroiwu IL, Obeagu EI, Elemchukwu Q, Ochei KC, Christian GS. Frequency of Transfusion Reactions Following Compatible Cross Matching of Blood: A Study in Owerri Metropolis. International Journal of Current Research and Academic Review. 2015;3(1):155-60.
  34. Ogar CO, Okoroiwu HU, Obeagu EI, Etura JE, Abunimye DA. Assessment of blood supply and usage pre-and during COVID-19 pandemic: a lesson from non-voluntary donation. Transfusion Clinique et Biologique. 2021;28(1):68-72.
  35. Busch, M. P., Bloch, E. M., & Kleinman, S. (2019). Prevention of transfusion-transmitted infections. Blood, The Journal of the American Society of Hematology, 133(17), 1854-1864.
  36. Brand, A. (2002). Immunological aspects of blood transfusions. Transplant immunology, 10(2-3), 183-190.
  37. Shander, A., Lobel, G. P., & Javidroozi, M. (2016). Transfusion practices and infectious risks. Expert review of hematology, 9(6), 597-605.
  38. Shah, N., Andrews, J., & Goodnough, L. T. (2015). Transfusions for anemia in adult and pediatric patients with malignancies. Blood Reviews, 29(5), 291-299.
  39. Friedman, M. T., Avadhani, V., Gilmore, S., & Madrigal, E. (2014). Blood transfusion in the 21st century. Discoveries, 2(1).
  40. Klatt, N. R., Chomont, N., Douek, D. C., & Deeks, S. G. (2013). Immune activation and HIV persistence: implications for curative approaches to HIV infection. Immunological reviews, 254(1), 326-342.
  41. Nesina, S., Katrin Helfer-Hungerbuehler, A., Riond, B., Boretti, F. S., Willi, B., Meli, M. L., … & Hofmann-Lehmann, R. (2015). Retroviral DNA—the silent winner: blood transfusion containing latent feline leukemia provirus causes infection and disease in naïve recipient cats. Retrovirology, 12, 1-18.
  42. Fasano, R. M., Meyer, E. K., Branscomb, J., White, M. S., Gibson, R. W., & Eckman, J. R. (2019). Impact of red blood cell antigen matching on alloimmunization and transfusion complications in patients with sickle cell disease: a systematic review. Transfusion Medicine Reviews, 33(1), 12-23.
  43. Rice, T. C., Pugh, A. M., Caldwell, C. C., & Schneider, B. S. P. (2017). Balance between the proinflammatory and anti-inflammatory immune responses with blood transfusion in sepsis. Critical Care Nursing Clinics, 29(3), 331-340.
  44. Tan, I. L., Smith, B. R., von Geldern, G., Mateen, F. J., & McArthur, J. C. (2012). HIV-associated opportunistic infections of the CNS. The Lancet Neurology, 11(7), 605-617.
  45. Paiardini, M., & Müller‐Trutwin, M. (2013). HIV‐associated chronic immune activation. Immunological reviews, 254(1), 78-101.
  46. Duguma, N., Tesfaye Kiya, G., Adissu Maleko, W., & Bimerew, L. G. (2021). Hematological parameters abnormalities and associated factors in HIV-positive adults before and after highly active antiretroviral treatment in Goba Referral Hospital, southeast Ethiopia: a cross-sectional study. SAGE Open Medicine, 9, 20503121211020175.
  47. Torres, M. E. U., Rodríguez, J. N. R., Ramos, J. L. S., & Gómez, F. A. (2014). Transfusion in palliative cancer patients: a review of the literature. Journal of Palliative Medicine, 17(1), 88-104.
  48. Guerado, E., Medina, A., Mata, M. I., Galvan, J. M., & Bertrand, M. L. (2016). Protocols for massive blood transfusion: when and why, and potential complications. European Journal of Trauma and Emergency Surgery, 42, 283-295.
  49. Abdullah, S., & Karunamoorthi, K. (2016). Malaria and blood transfusion: major issues of blood safety in malaria-endemic countries and strategies for mitigating the risk of Plasmodium parasites. Parasitology research, 115, 35-47.
  50. Osaro, E., & Charles, A. T. (2011). The challenges of meeting the blood transfusion requirements in Sub-Saharan Africa: the need for the development of alternatives to allogenic blood. Journal of blood medicine, 7-21.
  51. Vamvakas, E. C., & Blajchman, M. A. (2009). Transfusion-related mortality: the ongoing risks of allogeneic blood transfusion and the available strategies for their prevention. Blood, The Journal of the American Society of Hematology, 113(15), 3406-3417.
  52. World Health Organization. (2010). Screening donated blood for transfusion-transmissible infections: recommendations. World Health Organization.
CITE AS: Emmanuel Ifeanyi Obeagu, Getrude Uzoma Obeagu, Joseph Obiezu Chukwujekwu Ezeonwumelu, Frances Ugonne Ogunnaya, Anthonia Onyinye Ngwoke, Obioma Raluchukwu Emeka-Obi and Okechukwu Paul-Chima Ugwu (2023). Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. NEWPORT INTERNATIONAL JOURNAL OF BIOLOGICAL AND APPLIED SCIENCES (NIJBAS) 3(3): 9-15

DOWNLOAD PDF